Search clinical trials for: Interferon beta-1b (Betaseron, BAY86-5046)

Total 84 results

1
2
›

Bayer

Withdrawn

Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)

Multiple Sclerosis

Sweden, Denmark
Bayer

Completed

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Bayer

Completed

Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy

Heart Diseases | Cardiomyopathies

Italy, Spain, Germany, Poland, United Kingdom, Sweden, France
Bayer

Completed

Betaferon Use in Children and Adolescents With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Bayer

Completed

BENEFIT Extension Study

Multiple Sclerosis

Switzerland, Poland, France, Germany, Hungary, Spain, Sweden, Austria, Czech Republic, Italy, Slovenia, Israel, Belgium, Denmark, Netherlands, Canada, Norway, Finland
Bayer

Completed

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

Multiple Sclerosis, Relapsing-Remitting

Belgium, Israel, Sweden, United States, France, Switzerland, Ireland, Canada, Australia, Brazil, Austria, Poland, Germany, Hungary, Netherlands, Russian Federation, Spain, Argentina, Slovenia, Greece, Finland, Denmark, Ukraine, Italy, L... and more
Bayer

Completed

Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients

Multiple Sclerosis

France
Bayer

Completed

Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

Relapsing-Remitting Multiple Sclerosis

Germany
Bayer

Completed

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment (BEACON)

Relapsing Remitting Multiple Sclerosis (RRMS)

China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
Bayer

Completed

Depression and Fatigue in MS Patients Treated With Betaferon. (FADO)

Multiple Sclerosis

Poland
Bayer

Completed

China Betaferon Adherence, Coping and Nurse Support Study

Multiple Sclerosis, Chronic Progressive

China
Bayer

Completed

Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period (SEPLUS)

Multiple Sclerosis

France
Bayer

Completed

Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis (BREAK)

Multiple Sclerosis

Poland
Bayer

Completed

Physical Activity and Fatigue in Early Multiple Sclerosis (MS) (BEGIN)

Multiple Sclerosis

Switzerland, France, Germany, Indonesia, Korea, Republic of, Spain, Sweden, Thailand, Taiwan, Australia, Austria, Colombia, Czech Republic, Italy, Jordan, Kazakhstan, Lebanon, Mexico, Slovenia, United Kingdom, Bahrain, Egypt, United... and more
Bayer

Completed

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

Multiple Sclerosis

Canada, United States
Bayer

Completed

Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Multiple Sclerosis

Germany, Austria, United Kingdom, Israel, Belgium, Finland
Bayer

Completed

BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study

Multiple Sclerosis

Belgium, Italy, Spain, France, Germany, Canada, Switzerland, Austria, Denmark, Hungary, Netherlands, Poland, Israel, United Kingdom, Finland, Sweden, Norway, Czech Republic, Portugal, Slovenia
Bayer

Withdrawn

QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

Multiple Sclerosis, Relapsing-Remitting

Korea, Republic of
Bayer

Completed

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Bayer

Completed

BEYOND Pilot Study

Multiple Sclerosis | Relapsing-Remitting

United States
Bayer

Completed

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

Multiple Sclerosis, Relapsing-Remitting

United States
Bayer

Completed

BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

Relapsing Remitting MS (RRMS) | Secondary Progressive MS (SPMS)

France, Germany, Korea, Republic of, Saudi Arabia, Spain, Taiwan, Czech Republic, Italy, Jordan, Lebanon, Turkey, Israel, Portugal, Netherlands, Iran, Islamic Republic of
Bayer

Completed

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (CogniPlus)

Multiple Sclerosis

Turkey, Czechia, Hungary, Israel, Germany, France, Belgium, Greece, Netherlands, Egypt, Kazakhstan, Argentina, Portugal, Algeria, Saudi Arabia, Albania, Tunisia
Bayer

Completed

Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) (INFLUENCE)

Multiple Sclerosis

Poland
Bayer

Completed

Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

Multiple Sclerosis

China
Bayer

Completed

Physical Disability in Patients Treated With Betaferon

Multiple Sclerosis

Colombia
Bayer

Completed

Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b (ADHERENCE)

Multiple Sclerosis
Bayer

Completed

Betaferon® Regulatory Post-Marketing Surveillance

Multiple Sclerosis | Clinically Isolated System

Korea, Republic of
Bayer

Completed

Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron (START)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Bayer

Completed

Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors (POR-BetaPlus)

Secondary Progressive Multiple Sclerosis (SPMS) | Relapsing Remitting Multiple Sclerosis (RRMS)

Portugal
Bayer

Completed

Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon (BETAPREDICT)

Multiple Sclerosis

Germany
Bayer

Completed

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose (Beyond)

Multiple Sclerosis, Relapsing-Remitting

Belgium, Israel, United States, Canada, France, Switzerland, Ireland, Italy, Australia, Spain, Austria, Germany, Brazil, Netherlands, Poland, Russian Federation, Hungary, Slovenia, Argentina, Ukraine, Greece, Sweden, Finland, Latvia, No... and more
Bayer
Novartis Pharmaceuticals; Biogen; EPID Research; Merck Serono Europe Ltd

Completed

EPID Multiple Sclerosis Pregnancy Study

Multiple Sclerosis

Finland
Bayer

Completed

Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study (PROmyBETAapp)

Multiple Sclerosis

Germany
Bayer

Completed

US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector

Multiple Sclerosis

United States
Bayer

Completed

BAY86-5046 (Betaseron), Non Interventional Studies (BETAEVAL)

Multiple Sclerosis

Germany
Bayer

Completed

Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon (BetaSleep)

Multiple Sclerosis

Germany
Pfenex, Inc

Completed

Comparison Study of PF530 and Betaferon in Healthy Subjects

Multiple Sclerosis

Australia
Bayer

Completed

BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon

Multiple Sclerosis, Relapsing Remitting

Belgium, Bosnia and Herzegovina, Italy, Austria, Croatia, Czechia, France, Greece, Hungary, Spain, Switzerland
Bayer

Completed

PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon

Multiple Sclerosis

Germany
Rutgers, The State University of New Jersey
Bayer

Completed

Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis

Multiple Sclerosis

United States
Bayer

Completed

An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS (ABOVE)

Multiple Sclerosis, Relapsing-Remitting

United States, Canada
Bayer

Completed

Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif

Relapsing-remitting Multiple Sclerosis

France
Biogen

Completed

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy (PLENO)

Relapsing Remitting Multiple Sclerosis

Portugal
Biogen

Withdrawn

Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy (Frequency)

Relapsing Multiple Sclerosis
Bayer

Completed

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis (ROBUST)

Multiple Sclerosis, Relapsing-Remitting

United States
Claudio Gobbi
Ospedale Civico, Lugano

Completed

Natalizumab De-escalation With Interferon Beta-1b

Relapsing-remitting Multiple Sclerosis

Switzerland
Biogen
AMS Advanced Medical Services GmbH

Completed

A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis (PERFECT)

Multiple Sclerosis, Relapsing-Remitting

Germany
Nancy Hammond, MD
Kansas City Area Life Sciences Institute, Inc.

Completed

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

Multiple Sclerosis | Low Bone Density

United States
Claudio Gobbi
Bayer

Terminated

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

Switzerland

1
2
›

3

Subscribe